Here are the 10-Q quarterly reports from Nordicus Partners Corporation (NORD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NORD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NORD filings page.
Nordicus Partners Corp (NORD) reported no revenue for the three months ended June 30, 2026, and a net loss attributable to Nordicus of $2,276,302, compared with $1,206,886 a year earlier. Cash was $5,784 at quarter-end; operating activities used $159,844, versus $425,698 a year earlier. The company reported a $53,245,739 accumulated deficit and stated that current funds would not meet its needs for more than twelve months from issuance, creating substantial doubt about its ability to continue as a going concern.
Orocidin reported efficacy for QR-01 in dog and rat studies; its Phase IIa trial is anticipated in the first half of 2027. Bio-Convert anticipates Phase IIa trials in Europe beginning in the first half of 2027. On September 10, 2026, Nordicus issued a convertible note with $600,000 principal for $500,000 cash, bearing 5.0% annual interest and maturing June 10, 2027; the company also agreed to issue 250,000 commitment shares. Conversion is available to the lender only upon and during an event of default, and only from June 10, 2027, at 90% of the volume-weighted average price over the 10 trading days before a conversion request.
Nordicus Partners Corporation reported another pre-revenue quarter for the three months ended December 31, 2025, as it continues to build a portfolio of preclinical Nordic life sciences companies. Revenue was $0 compared with small related-party revenues in the prior year.
The company posted a net loss attributable to Nordicus of $1.23 million for the quarter and $3.95 million for the nine months, driven mainly by officer compensation, professional fees, and $1.32 million in research and development expenses over nine months. Comprehensive income for the nine months was positive $0.92 million, helped by $4.88 million in foreign currency translation gains.
At December 31, 2025, Nordicus held $189,297 in cash and total assets of $75.9 million, largely in goodwill and in-process R&D from acquisitions of Orocidin and Bio-Convert. Accumulated deficit reached $50.7 million, and management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
During the nine months, Nordicus raised about $3.9 million through private issuances of 1.69 million restricted shares, and subsequently raised $1.5 million from 547,036 shares at $2.75 per share. It also repurchased 57,642 shares under a limited buyback program. The portfolio now includes majority stakes in Orocidin, Bio-Convert and NoviThera, all targeting oral health and dermatology indications in preclinical stages.
Nordicus Partners Corporation (NORD) reported Q2 FY2026 results for the quarter ended September 30, 2025. The company recorded no revenue and a net loss of $1,511,474, or $0.08 per share. Operating expenses were $1,211,478, driven by officer compensation, R&D, and G&A. For the first six months, net loss totaled $2,718,360.
Liquidity remains tight. Cash was $242,155 as of September 30, 2025, after net cash used in operations of $2,188,401 in the six-month period. Financing cash inflows of $2,419,220 came from issuing 1,146,500 common shares. The company disclosed a going concern uncertainty due to nominal revenue, accumulated deficit of $49,503,208, and limited cash. Subsequent to quarter-end, it raised $618,750 via 225,000 restricted shares at $2.75 and repurchased 57,642 shares at $1.36.
Total assets were $75,882,821, including in-process R&D of $46,402,880 and goodwill of $27,696,030 tied to Orocidin A/S and Bio-Convert A/S. A fair-value decrease of $675,000 was recorded on the Mag Mile Capital investment over six months. Shares outstanding were 18,399,002 at quarter-end and 18,566,360 as of November 12, 2025.